Bristol-Myers Squibb Co. (NYSE:BMY) is the top pick in large cap pharmaceuticals. The analysts at J.P. Morgan see several near-term catalysts that could push shares higher. The J.P. Morgan price target for the stock is $60. Bristol-Myers Squibb Co (NYSE:BMY) shares after opening at $49.66 moved to $50.60 on last trade day and at the end of the day closed at $50.51. Company price to sales ratio in past twelve months was calculated as 5.11 and price to cash ratio as 18.50. Bristol-Myers Squibb Co (NYSE:BMY) showed a positive weekly performance of 3.44%.
Gilead Sciences Inc. (NASDAQ:GILD) is a top biotech that has been crushed in the sell-off and will report earnings this week. The J.P. Morgan price target is $100, and the consensus figure is $97.67. Gilead Sciences, Inc. (NASDAQ:GILD) shares advanced 2.29% in last trading session and ended the day on $71.60. GILD return on equity ratio is recorded as 28.30% and its return on assets is 13.70%. Gilead Sciences, Inc. (NASDAQ:GILD) yearly performance is 34.66%.
Incyte Corp. (NASDAQ:INCY) is another biotech name that the J.P. Morgan analysts are very positive on. They think the stock clearly has the most significant amount of near-term catalysts that could stem the bleeding and potentially propel shares materially higher. The firm’s price target is $80, and the consensus is at $72.08. A move to the J.P. Morgan target would be a huge 80% gain. Incyte Corporation (NASDAQ:INCY) shares moved up 6.53% in last trading session and was closed at $47.45, while trading in range of $44.54 – $47.49. Incyte Corporation (NASDAQ:INCY) year to date (YTD) performance is -6.28%.
Illumina Inc. (NASDAQ:ILMN) has also been mauled, and the stock is down 25% from its year-to-date peak. The J.P. Morgan price target is $190, and the consensus target is $166.40. Illumina, Inc. (NASDAQ:ILMN) weekly performance is 4.41%. On last trading day company shares ended up $141.21. Illumina, Inc. (NASDAQ:ILMN) distance from 50-day simple moving average (SMA50) is -10.49%. Analysts mean target price for the company is $166.40.
Mylan Inc. (NASDAQ:MYL) is one of the top generic drug companies and has been hammered. J.P. Morgan has a $65 target for the stock, and the consensus target is $61. Mylan Inc. (NASDAQ:MYL) shares after opening at $47.92 moved to $48.34 on last trade day and at the end of the day closed at $48.32. Company price to sales ratio in past twelve months was calculated as 2.60 and price to cash ratio as 61.69. Mylan Inc. (NASDAQ:MYL) showed a positive weekly performance of 5.69%.
Leave a Reply